MULTIFUNCTIONAL NANOMATERIALS AIMED AT GLIAL TUMORS FOR MOLECULAR IMAGING AND COMBINED TREATMENT BY CONTROLLED RELEASE OF PHARMACOS AND THERMOTHERAPY. (Q3193885): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
MULTIFUNCTIONAL NANOMATERIALS AIMED AT GLIAL TUMORS FOR MOLECULAR IMAGING AND COMBINED TREATMENT BY CONTROLLED RELEASE OF PHARMACOS AND THERMOTHERAPY. | |||
Revision as of 04:09, 9 October 2021
Project Q3193885 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | MULTIFUNCTIONAL NANOMATERIALS AIMED AT GLIAL TUMORS FOR MOLECULAR IMAGING AND COMBINED TREATMENT BY CONTROLLED RELEASE OF PHARMACOS AND THERMOTHERAPY. |
Project Q3193885 in Spain |
Statements
56,434.4 Euro
0 references
70,543.0 Euro
0 references
80.0 percent
0 references
1 January 2018
0 references
31 December 2020
0 references
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
0 references
29067
0 references
EL GLIOBLASTOMA MULTIFORME (GBM), ES EL TUMOR CEREBRAL PRIMARIO MAS FRECUENTE Y UNO DE LOS TUMORES MAS LETALES QUE EXISTEN. SU DIAGNOSTICO SE BASA EN PRUEBAS DE IMAGEN, FUNDAMENTALMENTE DE RESONANCIA MAGNETICA (MRI), Y CONFIRMACION HISTOLOGICA. AUNQUE EL DIAGNOSTICO NO INVASIVO POR IMAGEN HA MEJORADO EN LOS ULTIMOS AÑOS GRACIAS AL AVANCE TECNOLOGICO DE LA MRI, SIGUE SIN HABER BIOMARCADORES DE IMAGEN ESPECIFICOS QUE PERMITAN DIFERENCIARLO DE FORMA INEQUIVOCA OTRAS PATOLOGIAS, COMO LAS METASTASIS CEREBRALES, EL LINFOMA PRIMARIO DEL SISTEMA NERVIOSO CENTRAL, ABSCESOS CEREBRALES, OLIGONDENDROGLIOMAS, ETC., POR LO QUE LA CONFIRMACION DIAGNOSTICA SIGUE SIENDO HISTOLOGICA TRAS CIRUGIA. PERO AUN PEOR ES LA SITUACION RESPECTO A SU TRATAMIENTO. HOY EN DIA SIGUE OPTANDOSE POR UN TRATAMIENTO MUY AGRESIVO, QUE IMPLICA RESECCION QUIRURGICA, CUANDO ES ACCESIBLE, SEGUIDA DE RADIO Y QUIMIOTERAPIA. PERO A PESAR DE ELLO, LA MEDIANA DE SUPERVIVENCIA SE SITUA EN TORNO A LOS 15 MESES, ES DECIR, EN LA ACTUALIDAD NO EXISTE NINGUNA TERAPIA EFICAZ QUE PERMITA ALARGAR DE MANERA SIGNIFICATIVA LA SUPERVIVENCIA DE LOS PACIENTES DIAGNOSTICADOS DE GBM. POR TANTO, EXISTE UNA NECESIDAD URGENTE DE DESARROLLAR NUEVOS ABORDAJES DIAGNOSTICOS CON MAYOR ESPECIFICIDAD Y SOBRE TODO TERAPIAS ALTERNATIVAS MAS EFICACES. _x000D_ EN LOS ULTIMOS AÑOS SE HA HECHO UN ESFUERZO CONSIDERABLE EN EL DESARROLLO DE NUEVAS TERAPIAS BASADAS EN NANOTECNOLOGIA. LA MAYOR PARTE DE ESTOS TRABAJOS SE CENTRAN LA FABRICACION DE NANOMATERIALES, COMO LOS NANOLIPOSOMAS Y LAS NANOPARTICULAS POLIMERICAS, PARA EL TRANSPORTE Y LIBERACION CONTROLADA DE AGENTES TERAPEUTICOS; O NANOMATERIALES MAGNETICOS CON ALTOS VALORES DE SAR (SPECIFIC ABSORPTION RATE) PARA TERMOTERAPIA. SIN EMBARGO, LOS RESULTADOS OBTENIDOS HASTA EL MOMENTO NO HAN SUPUESTO UN AVANCE SIGNIFICATIVO RESPECTO A LA SUPERVIVENCIA GENERAL DE LOS PACIENTES. ENTRE LOS FACTORES RESPONSABLES DE ESTA SITUACION UN TANTO DESALENTADORA, ESTA POR UN LADO LA TERRIBLE NATURALEZA DE ESTOS TUMORES, PERO POR OTRO LADO, EN LA MAYORIA DE ESTOS NUEVOS ABORDAJES TERAPEUTICOS SE ECHA EN FALTA UN DISEÑO RACIONAL QUE TENGA EN CUENTA FACTORES TAN IMPORTANTES COMO LAS MULTIPLES BARRERAS BIOLOGICAS QUE HAY QUE SUPERAR IN VIVO PARA PODER LLEGAR AL TUMOR DE UNA MANERA EFICIENTE, EL TARGETING CELULAR ADECUADO, Y EL ESTUDIO SISTEMATICO DE LA FARMACOCINETICA Y BIODISTRIBUCION DE CADA NUEVO NANOSISTEMA TERAPEUTICO DESARROLLADO. _x000D_ EN ESTE SENTIDO, NUESTRO GRUPO HA REALIZADO UN IMPORTANTE TRABAJO DE CARACTERIZACION DEL COMPORTAMIENTO IN VIVO DE NANOPARTICULAS MAGNETICAS COMO POTENCIALES AGENTES PARA EL DIAGNOSTICO Y TERAPIA TUMORAL, TENIENDO EN CUENTA LOS DIVERSOS FACTORES (TAMAÑO, RECUBRIMIENTO, CARGA DE SUPERFICIE) QUE PUEDEN AFECTAR A SUS FARMACOCINETICAS, BIODISTRIBUCION, TIEMPOS DE CIRCULACION Y BIODISPONIBILIDAD. _x000D_ BASADOS EN ESTE CONOCIMIENTO PREVIO, PROPONEMOS LLEVAR A CABO EL DESARROLLO NUEVOS NANOMATERIALES MAGNETICOS MULTIFUNCIONALES DIRIGIDOS A GBM QUE PERMITAN REALIZAR DE MANERA SIMULTANEA UN DIAGNOSTICO ESPECIFICO MEDIANTE IMAGEN MOLECULAR POR MRI Y UN TRATAMIENTO EFICAZ MEDIANTE TERAPIA DIRIGIDA (TERANOSTICO TUMORAL). (Spanish)
0 references
GLIOBLASTOMA MULTIFORME (GBM) IS THE MOST COMMON PRIMARY BRAIN TUMOR AND ONE OF THE MOST LETHAL TUMORS. GBM DIAGNOSIS IS BASED ON IMAGING EXAMS, MAINLY MAGNETIC RESONANCE IMAGING (MRI), AND HISTOLOGICAL CONFIRMATION. ALTHOUGH THE NON-INVASIVE IMAGING-BASED DIAGNOSIS HAS IMPROVED OVER THE LAST YEARS THANKS TO THE TECHNOLOGICAL ADVANCES OF MRI, THERE IS NO ANY SPECIFIC IMAGING BIOMARKER THAT ALLOW GBM TO BE UNEQUIVOCALLY DIFFERENTIATED FROM OTHER PATHOLOGIES, SUCH AS BRAIN METASTASES, PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, BRAIN ABSCESSES, OLIGONDENDROGLIOMAS, ETC., AND THEREFORE HISTOLOGICAL CONFIRMATION AFTER SURGERY REMAINS THE GOLD STANDARD FOR DIAGNOSIS. IN REGARD TO TREATMENT, THE SITUATION IS EVEN WORSE. CURRENTLY, THE STANDARD TREATMENT PROCEDURE IS VERY AGGRESSIVE, INVOLVING SURGICAL RESECTION, WHEN ACCESSIBLE, FOLLOWED BY RADIO AND CHEMOTHERAPY. IN SPITE OF THIS, THE MEDIAN SURVIVAL IS AROUND 15 MONTHS, THAT IS, AT PRESENT THERE IS NO EFFECTIVE THERAPY THAT CAN SIGNIFICANTLY EXTEND THE OVERALL SURVIVAL OF PATIENTS DIAGNOSED WITH GBM. THEREFORE, THERE IS AN URGENT NEED TO DEVELOP NEW DIAGNOSTIC APPROACHES WITH IMPROVED SPECIFICITY AND, ABOVE ALL, MORE EFFECTIVE THERAPIES._x000D_ OVER THE LAST YEARS A CONSIDERABLE EFFORT HAS BEEN MADE ON THE DEVELOPMENT OF NEW THERAPIES BASED ON NANOTECHNOLOGY. MOST OF THIS WORK IS FOCUSED ON THE DEVELOPMENT OF NANOMATERIALS, SUCH AS NANOLIPOSOMES AND POLYMER NANOPARTICLES, FOR THE TRANSPORT AND CONTROLLED DELIVERY OF THERAPEUTIC DRUGS; OR MAGNETIC NANOMATERIALS WITH HIGH SPECIFIC ABSORPTION RATES (SAR) FOR THERMOTHERAPY. HOWEVER, THE RESULTS OBTAINED SO FAR DID NOT HAVE ANY SIGNIFICANT IMPACT ON THE OVERALL PATIENTS SURVIVAL. ONE OF THE REASONS FOR THIS SOMEWHAT DISCOURAGING SITUATION IS, ON THE ONE HAND, THE DEVASTATING NATURE OF THESE TUMORS, BUT ON THE OTHER HAND, IT CAN ALSO BE ATTRIBUTED TO THE FACT THAT MOST OF THESE NEW THERAPEUTIC APPROACHES LACK A RATIONAL DESIGN THAT TAKES INTO ACCOUNT FACTORS AS IMPORTANT AS THE MULTIPLE BIOLOGICAL BARRIERS THAT HAVE TO BE OVERCOME IN VIVO TO EFFICIENTLY REACH THE TUMOR, THE USE OF PROPER CELLULAR TARGETS, AND THE SYSTEMATIC STUDY OF THE PHARMACOKINETICS AND BIODISTRIBUTION OF EACH NEW THERAPEUTIC NANOSYSTEM DEVELOPED._x000D_ IN THIS REGARD, OUR GROUP HAS CARRIED OUT A SIGNIFICANT AMOUNT OF WORK IN CHARACTERIZATION OF THE IN VIVO BEHAVIOR OF MAGNETIC NANOPARTICLES AS POTENTIAL AGENTS FOR TUMOR DIAGNOSIS AND THERAPY, TAKING INTO ACCOUNT THE VARIOUS FACTORS (SIZE, COATING, SURFACE LOADING) THAT CAN AFFECT THEIR PHARMACOKINETICS, BIODISTRIBUTION, CIRCULATION TIMES AND BIOAVAILABILITY._x000D_ ON THE BASIS OF THIS PRIOR KNOWLEDGE, WE PROPOSE THE DEVELOPMENT OF NEW MULTIFUNCTIONAL MAGNETIC NANOMATERIALS TARGETED TO GBM FOR SPECIFIC DIAGNOSIS USING MOLECULAR MRI AND EFFECTIVE TARGETED THERAPY (TUMOR THERANOSTICS). (English)
0 references
Málaga
0 references
Identifiers
CTQ2017-86655-R
0 references